Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>Our base case continues to be for near-term consolidation while the market determines the implications of states’ reopening (i.e., the “wait-and-see” phase). Until this consolidation period resolves below support or above resistance we are maintaining a relatively neutral stance considering the wide range of outcomes. Many major indexes are testing logical resistance and until we see breakouts it is hard to get too bullish. In this report we highlight attractive stocks from a RS perspective.</p>

Our base case continues to be for near-term consolidation while the market determines the implications of states’ reopening (i.e., the “wait-and-see” phase). Until this consolidation period resolves below support or above resistance we are maintaining a relatively neutral stance considering the wide range of outcomes. Many major indexes are testing logical resistance and until we see breakouts it is hard to get too bullish. In this report we highlight attractive stocks from a RS perspective.

U.S. Equity Strategy: Round Trip Back To Resistance

Healthcare Specialist

Winnie Wong

Equity Bottom-Up

<p><a href="https://www.smartkarma.com/entities/15060" target="_blank" data-smartkarma-citation="entities:15060:1">Nektar Therapeutics (NKTR US)</a> 's share price soared 11.02% to $84 on Wednesday after it <a href="http://ir.nektar.com/news-releases/news-release-details/bristol-myers-squibb-and-nektar-therapeutics-announce-global" target="_blank">announced</a> the world's largest ever biotech deal with <a href="https://www.smartkarma.com/entities/1133" target="_blank" data-smartkarma-citation="entities:1133:1">Bristol Myers Squibb Co (BMY US)</a> (up 2.32%) to jointly develop and commercialise Nektar's NKTR-214 with Bristol's blockbuster cancer drug Opdivo and CTLA-4 drug Yervoy.</p><h2>Deal Highlights</h2><p>Netkar will receive total upfront payments of $1.85 billion, consisting of $1 billion in cash and $850 million in equity.  Bristol will purchase 8.3 million shares of Netkar at…</p>

Nektar Therapeutics (NKTR US) 's share price soared 11.02% to $84 on Wednesday after it announced the world's largest ever biotech deal with Bristol Myers Squibb Co (BMY US) (up 2.32%) to jointly develop and commercialise Nektar's NKTR-214 with Bristol's blockbuster cancer drug Opdivo and CTLA-4 drug Yervoy.Deal HighlightsNetkar will receive total upfront payments of $1.85 billion, consisting of $1 billion in cash and $850 million in equity.  Bristol will purchase 8.3 million shares of Netkar at…

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

<p>We opened a new long position today in <a href="https://www.smartkarma.com/entities/15201" target="_blank" data-smartkarma-citation="entities:15201:1">Ophthotech Corp (OPHT US)</a>, an emerging biotechnology company that is developing novel drugs for wet-type age-related macular degeneration (AMD). The company has an upcoming catalyst (results of a phase 3 trial for Fovista, its novel wet-AMD therapy), that could move the stock price. We present our investment thesis for the company and valuation of the common stock (risk-adjusted NPV).</p>

We opened a new long position today in Ophthotech Corp (OPHT US), an emerging biotechnology company that is developing novel drugs for wet-type age-related macular degeneration (AMD). The company has an upcoming catalyst (results of a phase 3 trial for Fovista, its novel wet-AMD therapy), that could move the stock price. We present our investment thesis for the company and valuation of the common stock (risk-adjusted NPV).

New Long Position: Novel Drug for Wet-AMD, a Common Cause of Blindness, and Upcoming Catalyst.

United States

Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.  The Company's product pipeline is comprised of early to late stage drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Nektar Therapeutics (NKTR US)

U.S. Equity Strategy: Round Trip Back To Resistance

Our base case continues to be for near-term consolidation while the market determines the implications of states’ reopening (i.e., the...

Vermilion Research

Nektar: New Pathways To Smarter Deals?

Nektar Therapeutics (NKTR US) 's share price soared 11.02% to $84 on Wednesday after it announced the world's largest ever biotech deal with...

Winnie Wong

New Long Position: Novel Drug for Wet-AMD, a Common Cause of Blindness, and Upcoming Catalyst.

We opened a new long position today in Ophthotech Corp (OPHT US), an emerging biotechnology company that is developing novel drugs for wet-type...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)